Antibody Information
General Information of This Antibody
| Antibody ID | ANI0LHFOP |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Trastuzumab N297A |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Antigen Info | ||||
The Activity Data of This Antibody
| Antibody Activity Information 1 | [1] | |||||
|
Dissociation Constant (Kd)
|
>10 |
uM
|
MDA-MB-231 cells | CVCL_0062 | ||
|---|---|---|---|---|---|---|
| Antigen Expression | Negative expression (HER2-) | |||||
| Antibody Function | Confirm the effect of the drug conjugation with the anti-HER2 mAb and ADC on binding activity to cell line. | |||||
| Antibody Antigen Binding Assay | ADC and mAb were tested for HER2-binding affinity by cell-based enzyme-linked immunosorbent assay (ELISA). For this test, the human breast cancer cell lines KPL-4 (HER2 positive) and MDA-MB-231 (HER2 negative) were used. | |||||
| Antibody Activity Information 2 | [1] | |||||
|
Dissociation Constant (Kd)
|
81
|
pM
|
KPL-4 cells | CVCL_5310 | ||
| Antigen Expression | Low HER2 expression (HER2+) | |||||
| Antibody Function | Confirm the effect of the drug conjugation with the anti-HER2 mAb and ADC on binding activity to cell line. | |||||
| Antibody Antigen Binding Assay | ADC and mAb were tested for HER2-binding affinity by cell-based enzyme-linked immunosorbent assay (ELISA). For this test, the human breast cancer cell lines KPL-4 (HER2 positive) and MDA-MB-231 (HER2 negative) were used. | |||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
ADC MMAE/F 4+2 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 77.50% (Day 24) | Low HER2 expression (HER2+) | ||
| Method Description |
HCC1954-TDR breast tumor model shows very low HER2 expression with intratumor heterogeneity,representing refractory breast tumors. The HCC1954-TDR cell line was established by continuous treatment with T-DM1 for 8 months. Once tumors reached an average volume of 125mm3,mice were administered with a single dose of the MMAE/F 4+2 ADC (1 mg/kg).
Click to Show/Hide
|
||||
| In Vivo Model | Breast cancer CDX model | ||||
| In Vitro Model | Breast cancer | Breast cancer cells | Homo sapiens | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.10% (Day 24) | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The in vivo validated model was a xenograft model of human breast tumor consisting of HER2-positive JIMT-1 cells and HER2-negative MDA-MB-231 cells (4:1 ratio) transferred into immunodeficient mice. This admixed tumor grew aggressively and reached a palpable size (100-150 mm 3 ) in most mice 7 days after orthotopic transplantation. Tumor-bearing mice were treated with each ADC at 3 mg/kg.
Click to Show/Hide
|
||||
| In Vivo Model | Breast cancer CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells/MDA-MB-231 cells | CVCL_2077/CVCL_0062 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.02 nM
|
Moderate HER2 expression (HER2++) | ||
| Method Description |
ADCs were evaluated in vitro cytotoxicity in HER2-positive (KPL-4,JIMT-1,and SKBR-3) and -negative (MDA-MB-231) breast cancer cell lines,human embryonic kidney 293 (HEK293) cells,and human hepatocyte carcinoma (HepG2) cells. All cells were cultured at 37°C under 5% CO2 and passaged before becoming fully confluent up to 20 passages.
|
||||
| In Vitro Model | Breast inflammatory carcinoma | KPL-4 cells | CVCL_5310 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.02 nM
|
Low HER2 expression (HER2+) | ||
| Method Description |
ADCs were evaluated in vitro cytotoxicity in HER2-positive (KPL-4,JIMT-1,and SKBR-3) and -negative (MDA-MB-231) breast cancer cell lines,human embryonic kidney 293 (HEK293) cells,and human hepatocyte carcinoma (HepG2) cells. All cells were cultured at 37°C under 5% CO2 and passaged before becoming fully confluent up to 20 passages.
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.18 nM
|
Moderate HER2 expression (HER2++) | ||
| Method Description |
ADCs were evaluated in vitro cytotoxicity in HER2-positive (KPL-4,JIMT-1,and SKBR-3) and -negative (MDA-MB-231) breast cancer cell lines,human embryonic kidney 293 (HEK293) cells,and human hepatocyte carcinoma (HepG2) cells. All cells were cultured at 37°C under 5% CO2 and passaged before becoming fully confluent up to 20 passages.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
ADC MMAE/F 2+4 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 87.60% (Day 24) | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The in vivo validated model was a xenograft model of human breast tumor consisting of HER2-positive JIMT-1 cells and HER2-negative MDA-MB-231 cells (4:1 ratio) transferred into immunodeficient mice. This admixed tumor grew aggressively and reached a palpable size (100-150 mm 3 ) in most mice 7 days after orthotopic transplantation. Tumor-bearing mice were treated with each ADC at 3 mg/kg.
Click to Show/Hide
|
||||
| In Vivo Model | Breast cancer CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells/MDA-MB-231 cells | CVCL_2077/CVCL_0062 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.02 nM
|
Moderate HER2 expression (HER2++) | ||
| Method Description |
ADCs were evaluated in vitro cytotoxicity in HER2-positive (KPL-4,JIMT-1,and SKBR-3) and -negative (MDA-MB-231) breast cancer cell lines,human embryonic kidney 293 (HEK293) cells,and human hepatocyte carcinoma (HepG2) cells. All cells were cultured at 37°C under 5% CO2 and passaged before becoming fully confluent up to 20 passages.
|
||||
| In Vitro Model | Breast inflammatory carcinoma | KPL-4 cells | CVCL_5310 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.03 nM
|
Low HER2 expression (HER2+) | ||
| Method Description |
ADCs were evaluated in vitro cytotoxicity in HER2-positive (KPL-4,JIMT-1,and SKBR-3) and -negative (MDA-MB-231) breast cancer cell lines,human embryonic kidney 293 (HEK293) cells,and human hepatocyte carcinoma (HepG2) cells. All cells were cultured at 37°C under 5% CO2 and passaged before becoming fully confluent up to 20 passages.
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.23 nM
|
Moderate HER2 expression (HER2++) | ||
| Method Description |
ADCs were evaluated in vitro cytotoxicity in HER2-positive (KPL-4,JIMT-1,and SKBR-3) and -negative (MDA-MB-231) breast cancer cell lines,human embryonic kidney 293 (HEK293) cells,and human hepatocyte carcinoma (HepG2) cells. All cells were cultured at 37°C under 5% CO2 and passaged before becoming fully confluent up to 20 passages.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
ADC MMAE/F 2+2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.03 nM
|
Moderate HER2 expression (HER2++) | ||
| Method Description |
ADCs were evaluated in vitro cytotoxicity in HER2-positive (KPL-4,JIMT-1,and SKBR-3) and -negative (MDA-MB-231) breast cancer cell lines,human embryonic kidney 293 (HEK293) cells,and human hepatocyte carcinoma (HepG2) cells. All cells were cultured at 37°C under 5% CO2 and passaged before becoming fully confluent up to 20 passages.
|
||||
| In Vitro Model | Breast inflammatory carcinoma | KPL-4 cells | CVCL_5310 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.05 nM
|
Low HER2 expression (HER2+) | ||
| Method Description |
ADCs were evaluated in vitro cytotoxicity in HER2-positive (KPL-4,JIMT-1,and SKBR-3) and -negative (MDA-MB-231) breast cancer cell lines,human embryonic kidney 293 (HEK293) cells,and human hepatocyte carcinoma (HepG2) cells. All cells were cultured at 37°C under 5% CO2 and passaged before becoming fully confluent up to 20 passages.
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.34 nM
|
Moderate HER2 expression (HER2++) | ||
| Method Description |
ADCs were evaluated in vitro cytotoxicity in HER2-positive (KPL-4,JIMT-1,and SKBR-3) and -negative (MDA-MB-231) breast cancer cell lines,human embryonic kidney 293 (HEK293) cells,and human hepatocyte carcinoma (HepG2) cells. All cells were cultured at 37°C under 5% CO2 and passaged before becoming fully confluent up to 20 passages.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.